2-氨基-5-苯基噻吩-3-甲酸甲酯 | 61325-02-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氨基-5-苯基噻吩-3-甲酸甲酯
• 中文别名: 2-氨基-5-苯基噻吩-3-羧酸乙酯
• 英文名称: 2-amino-5-phenylthiophene-3-carboxylic acid methyl ester
• 英文别名: methyl 2-amino-5-phenylthiophene-3-carboxylate；2-amino-5-phenyl-thiophene-3-carboxylic acid methyl ester；2-amino-5-phenylthiophen-3-carboxylic acid methyl ester；Methyl 2-amino-5-phenyl-thiophene-3-carboxylate；2-Amino-5-phenyl-3-thiophencarbonsaeuremethylester
• CAS: 61325-02-8
• 化学式: C₁₂H₁₁NO₂S
• mdl: MFCD02090936
• 分子量: 233.291
• InChiKey: QKYRXLPXSJZIQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-氨基-5-苯基噻吩-3-甲酸甲酯 在 三氯氧磷 作用下， 以 氯仿 为溶剂， 反应 8.5h， 生成 4-oxo-2-phenyl-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-7-carbonitrile
  参考文献：
  名称：

  Synthesis and antiallergy activity of 4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidines

  摘要：

  A series of 4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidines with substitutions in the 2, 3, and 7 positions was prepared. The compounds were evaluated in the rat passive cutaneous anaphylaxis test for antiallergy activity. Several compounds had potent oral activity and were found to be superior to disodium cromoglycate and doxantrazole. Structure-activity relationships are discussed.

  DOI：

  10.1021/jm00139a021
• 作为产物：
  描述：

  Methyl 2-cyano-4-phenylbut-2-enoate 在 sulfur 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-氨基-5-苯基噻吩-3-甲酸甲酯
  参考文献：
  名称：

  Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors

  摘要：

  Checkpoint kinase-1 (Chk1, CHEK1) is a Ser/Thr protein kinase that mediates the cellular response to DNA-damage. A novel class of 2-ureido thiophene carboxamide urea (TCU) Chk1 inhibitors is described. Inhibitors in this chemotype were optimized for cellular potency and selectivity over Cdk1. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.016

文献信息

• Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102600A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式I的化合物，可选地以药物可接受的盐、溶剂化物、多晶型、前药、互变异构体、外消旋体、对映体、非对映体或其混合物的形式，该化合物在治疗、改善或预防病毒性疾病方面有用。此外，还公开了特定的组合疗法。
• [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES<br/>[FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE SYNTHÈSE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：BIODIM LAB

  公开号：WO2012137181A1

  公开（公告）日：2012-10-11

  The present invention relates to compounds of formula (1) as claimed in claim 1, their use in the treatment or the prevention of viral disorders, including HIV. (Formula I)

  本发明涉及权利要求1中所述的式(1)化合物，及其用于治疗或预防病毒疾病，包括HIV。
• Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102601A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式II的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、前药、互变异构体、消旋体、对映体或二对映体或其混合物的形式存在，用于治疗、改善或预防病毒性疾病。此外，还披露了特定的联合疗法。
• Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease
  作者：Claudia Mugnaini、Alessandro Rabbito、Antonella Brizzi、Nastasja Palombi、Stefania Petrosino、Roberta Verde、Vincenzo Di Marzo、Alessia Ligresti、Federico Corelli

  DOI：10.1016/j.ejmech.2018.09.070

  日期：2019.1

  A set of CB2R ligands, based on the thiophene scaffold, was synthesized and evaluated in in vitro assays. Compounds 8c-i, k, l, bearing the 3-carboxylate and 2-(adamantan-1-yl)carboxamido groups together with apolar alkyl/aryl substituents at 5-position or at 4- and 5-positions of the thiophene ring possess high CB2R affinity at low nanomolar concentration, good receptor selectivity, and agonistic

  合成了一组基于噻吩骨架的CB2R配体，并在体外分析中进行了评估。在噻吩环的5-位或4-和5-位带有3-羧酸根和2-（金刚烷-1-基）羧酰胺基以及非极性烷基/芳基取代基的化合物8c-i，k，l具有在低纳摩尔浓度下具有高CB2R亲和力，良好的受体选择性和激动性功能活性。在过敏性接触性皮炎的实验模型中对全受体激动剂8g（在受体亲和力和选择性之间取得了最佳平衡）进行了体外测试，结果证明能够以10μM的浓度阻断HaCaT细胞中MCP-2的释放。
• Azo dyes
  申请人：Asiri Abdullah Mohamed

  公开号：US20100081823A1

  公开（公告）日：2010-04-01

  The azo dyes relate to thiophene azo dyes of the general formula: where R1 is Cyano or C1-C5 alkoxy carbonyl; R2 is hydrogen, halogene, C1-C2 alkyl, phenyl, or substituted phenyl; and R3 is C1-C5 alkoxy carbonyl, C1-C4 alkanoyl, benzoyl, phenyl, alkyl substituted phenyl, or alkoxy phenyl; or R2 and R3 are fused cycloalkane with C3-C5.

  偶氮染料涉及一般式为的噻吩偶氮染料：其中R1为氰基或C1-C5烷氧羰基；R2为氢、卤素、C1-C2烷基、苯基或取代苯基；R3为C1-C5烷氧羰基、C1-C4烷酰基、苯甲酰基、苯基、烷基取代苯基或烷氧基苯基；或者R2和R3为融合的C3-C5环烷烃。